Janux ( JANX ) R&D Soars Revenue Misses
Janux Therapeutics ( NASDAQ:JANX ) , a clinical-stage biotechnology company focused on developing next-generation immunotherapies, reported second quarter results on August 7, 2025. The main headline: the company posted a net loss as it continued to invest heavily in its pipeline, with GAAP ...
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Harrow ( NASDAQ:HROW ) , Janux Therapeutics ( NASDAQ:JANX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ladenburg Thalmann analyst Aydin Huseynov initiated coverage on KALA BIO, Inc.
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics ( NASDAQ: JANX ) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P ...
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Janux Therapeutics ( NASDAQ:JANX )
JANX007 showed strong efficacy in metastatic castration-resistant prostate cancer, with 100% achieving PSA50 declines. The therapy demonstrated durability irrespective of prior treatments. Benzinga shares with you top insiders news On Monday, Janux Therapeutics, Inc.
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Credo Technology Group ( NASDAQ:CRDO ) , Aptorum Gr ( NASDAQ:APM )
Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results issued guidance that was above estimates. Credo Technology Group shares jumped 40.2% to $67.00 in the pre-market trading ...
Janux Therapeutics ( JANX ) Moves 6.5% Higher: Will This Strength Last?
Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Janux Therapeutics, Inc. ( JANX ) Reports Q2 Loss, Tops Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday - AC Immune ( NASDAQ:ACIU ) , Ambarella ( NASDAQ:AMBA )
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. AMBA rose sharply during Friday's session following strong first-quarter earnings and upbeat second-quarter guidance.
Analyst Ratings For Janux Therapeutics
In the preceding three months, 9 analysts have released ratings for Janux Therapeutics ( NASDAQ:JANX ) , presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares ...
Janux Therapeutics Options Trading: A Deep Dive into Market Sentiment - Janux Therapeutics ( NASDAQ:JANX )
Benzinga's options scanner has just identified more than 10 option transactions on Janux Therapeutics JANX, with a cumulative value of $516,310. Concurrently, our algorithms picked up 4 puts, worth a total of 166,310.
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q1 Loss, Misses Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Janux Therapeutics ( JANX ) Maintain Its Recent Price Strength
Janux Therapeutics (JANX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Janux ( JANX ) Rises Almost 50% in a Week on Buyout Rumors
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.
Janux Therapeutics ( JANX ) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden.
Why Is Janux Therapeutics Stock Trading Higher On Thursday? - Janux Therapeutics ( NASDAQ:JANX )
Janux Therapeutics Inc JANX shares are trading higher following Wednesday's reports suggesting the company is considering a possible sale following interest from larger pharmaceutical firms.
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Janux Therapeutics ( NASDAQ:JANX ) , Alpine Immune Sciences ( NASDAQ:ALPN ) , Enliven Therapeutics ( NASDAQ:ELVN )
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. ELVN rose sharply during Thursday's session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
Wall Street Analysts Think Janux Therapeutics ( JANX ) Could Surge 40.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 40.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stocks Heat Up, Driven By A Spate Of Billion-Dollar Deals
Biotech Stocks Heat Up As Arvinas Scores Licensing Deal And Janux Reportedly Explores Options Investor's Business Daily ...
Why Janux Therapeutics Stock Soared as the Market Sagged Today
One of the hotter biotech companies on the scene might be changing owners before long.
After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics ( JANX )
Janux Therapeutics (JANX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Janux Therapeutics ( JANX ) Upgraded to Buy: Here's What You Should Know
Janux Therapeutics (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Janux Therapeutics ( JANX ) Could Rally 57.47%: Here's is How to Trade
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics ( NASDAQ:JANX )
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly.
Biotech ETFs to Watch
The life science sector can certainly be risky, and ETFs are a good way to enter more safely than by investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update.
5 Stocks That More Than Doubled in February
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
Recent Price Trend in Janux Therapeutics, Inc. ( JANX ) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Could The Recent Rally Be Buoying This Biotech Stock?
TG Therapeutics Issues In-Line Report, But TGTX Stock Surges On Biotech Rally Investor's Business Daily ...
Janux Therapeutics Scores Relative Strength Rating Upgrade
Janux Therapeutics ( JANX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 89 to 99. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings - Janux Therapeutics ( NASDAQ:JANX ) , Hims & Hers Health ( NYSE:HIMS )
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40. Utilities shares rose by 1.2% on Tuesday.
Biopharma Stock News Bite - Janux Therapeutics, Inc. ( Nasdaq: JANX ) Spikes over 200% on News Making it Nasdaq's Top Gainer
Biopharma Stock News Bite - Janux Therapeutics, Inc. ( Nasdaq: JANX ) Spikes over 200% on News Making it Nasdaq's ... ...
Why Is JANX Therapeutics Stock Trading Higher Today? - Janux Therapeutics ( NASDAQ:JANX )
On Monday, Janux Therapeutics Inc JANX released updated data for its JANX007 in metastatic castration-resistant prostate cancer and JANX008 in late-stage solid tumors. JANX007 is in a Phase 1a trial in heavily pretreated subjects with advanced or metastatic prostate cancer ( mCRPC ) .
Crude Oil Gains 1%; Macy's Plans To Close 150 Stores - Janux Therapeutics ( NASDAQ:JANX ) , Hims & Hers Health ( NYSE:HIMS )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&P 500 also fell, dropping, 0.03% to 5,067.80. Utilities shares rose by 1.5% on Tuesday.
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday - Norwegian Cruise Line ( NYSE:NCLH )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Norwegian Cruise Line Holdings Ltd. NCLH rose sharply during Tuesday's session following better-than-expected fourth-quarter revenues.
Biotech Stock Nearly Triples On 'Significant Opportunity' In Cancer Treatment
Janux Therapeutics ( JANX ) unveiled promising results for a prostate cancer treatment on Tuesday. The biotech stock nearly tripled, hitting a record high. The company is testing multiple dosing regimens in patients with metastatic prostate cancer.
Nasdaq Rises 50 Points; Lowe's Earnings Top Views - Janux Therapeutics ( NASDAQ:JANX ) , Infobird Co ( NASDAQ:IFBD )
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose 0.31% to 16,026.43. The S&P 500 also rose, gaining, 0.10% to 5,074.75.
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Advent Technologies Hldgs ( NASDAQ:ADN ) , Aarons ( NYSE:AAN )
Shares of TransMedics Group, Inc. TMDX rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. The company posted quarterly earnings of 12 cents per share, compared to market estimates for a loss of 3 ...
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Amplitude ( NASDAQ:AMPL ) , AtlasClear Holdings ( AMEX:ATCH )
Shares of International Flavors & Fragrances Inc. IFF fell during Wednesday's session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share. International Flavors & Fragrances shares dipped 8.4% to ...
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday - Toll Brothers ( NYSE:TOL ) , Exelon ( NASDAQ:EXC ) , Garmin ( NYSE:GRMN )
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. Shares of Toll Brothers, Inc. TOL gained during Wednesday's session after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.
Janux Therapeutics, Inc. ( JANX ) Moves 5.6% Higher: Will This Strength Last?
Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inovio ( INO ) Moves 17.4% Higher: Will This Strength Last?
Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Janux Therapeutics, Inc. ( JANX ) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. ( JANX ) : Can the Stock Really Move This High?
The consensus price target hints at a 220.2% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday - Adaptive Biotechnologies ( NASDAQ:ADPT ) , Accolade ( NASDAQ:ACCD )
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. AZTA rose on Tuesday after the company reported better-than-expected fourth-quarter financial results. Azenta posted adjusted earnings of 13 cents per share, beating market estimates of 2 ...
$27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying - Janux Therapeutics ( NASDAQ:JANX ) , American States Water ( NYSE:AWR )
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Janux Therapeutics, Inc. ( JANX ) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Janux Therapeutics, Inc. (JANX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
